Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

By Global News Feed

NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.

More here:
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

By Global News Feed

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.

Continue reading here:
electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

By Global News Feed

BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.

Continue reading here:
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics

By Global News Feed

VALENCIA, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will host a virtual KOL event on December 19, 2023 at 11:00 AM ET, led by Suji Jeong PhD (Founding Partner, The SJR Group), featuring Phil Nicklin (Senior Analyst, LifeSci Consulting) and Dr. Ashley Mishoe, PharmD (Vice President of Regulatory Affairs and Quality Assurance, PharmaLogic). They will discuss emerging trends in the radiotherapeutics landscape, a market that is projected to have a $30 billion potential in the next five years, a prospect that is capturing the attention of investors and companies alike. To register, click here.

Link:
Nusano to Host December 19 Virtual KOL Event on Emerging Trends in Radiotherapeutics

Bon Natural Life Limited Announces Major Breakthrough in Apple Polyphenol Technology, Set to Boost Fiscal 2024 Sales

By Global News Feed

XI’AN, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solution providers in the natural, health and personal care industries, today announced that the Company has achieved significant breakthrough in apple polyphenol extraction technology. This development is set to drive considerable growth in BON's apple polyphenol products in the upcoming fiscal year.

Read the rest here:
Bon Natural Life Limited Announces Major Breakthrough in Apple Polyphenol Technology, Set to Boost Fiscal 2024 Sales

Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three…

By Global News Feed

PALO ALTO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has signed an insurance coverage agreement for ELYXYB® with a national PBM, for their Medicare population potentially expanding coverage of ELYXYB®.

Read the rest here:
Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three...

Rose Hill and ACS Laboratory Join Forces to Pioneer Psilocybin Testing Standards

By Global News Feed

Landmark Partnership Aims to Establish Elevated Benchmark for Psilocybin Testing, Expand Research Efforts, and Enhance Industry Education Landmark Partnership Aims to Establish Elevated Benchmark for Psilocybin Testing, Expand Research Efforts, and Enhance Industry Education

Read more from the original source:
Rose Hill and ACS Laboratory Join Forces to Pioneer Psilocybin Testing Standards

→←